Connect your AI

Bristol-Myers Squibb BMY Treasury Stock

Treasury Stock at other companies

PfizerPFE

$115.19B+0.2%

Johnson & JohnsonJNJ

$75.86B+0.2%

Merck & Co.MRK

$63.75B+7.3%

AlkermesALKS

$502.52M+11.7%

ImmunityBio, Inc.IBRX

——

Other financials

Income statement

Revenue$11.5B+2.6%

Gross profit$8.1B-1.2%

Net income$2.7B+9.0%

EPS (diluted)$1.31+9.2%

Balance sheet

Cash & equivalents$9.6B-12.0%

Total debt$44.7B-10.5%

Total equity$20.1B+15.4%

Total assets$86.5B-6.4%

Cash flow

Operating cash flow$1.1B-43.5%

CapEx$347.0M+33.5%

Free cash flow$757.0M-55.3%

Valuation

Market cap$126.79B+31.1%

Enterprise value$161.88B+21.3%

P/E17.4×-2.0×

P/S2.6×+0.6×

Profitability

Gross margin70.5%0.0pp

Net margin15%+3.8pp

FCF margin24.6%-2.9pp

Returns & leverage

Return on equity38.8%+7.3pp

Debt / equity2.2×-0.6×

Current ratio1.4×+0.1×

Where this comes from

Reported directly by Bristol-Myers Squibb in its filing.

Tagged under the XBRL concept us-gaap:TreasuryStockCommonValue.

The official record: Bristol-Myers Squibb’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bristol-Myers Squibb's treasury stock.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Bristol-Myers Squibb's treasury stock?: Bristol-Myers Squibb (BMY) reported treasury stock of $43.52B in Q1 2026.
How has Bristol-Myers Squibb's treasury stock changed year-over-year?: Bristol-Myers Squibb's treasury stock decreased by 0.2% year-over-year, from $43.6B to $43.52B.
What is the long-term trend for Bristol-Myers Squibb's treasury stock?: Over 5 years (2020 to 2025), Bristol-Myers Squibb's treasury stock has grown at a 10.7% compound annual growth rate (CAGR), from $26.24B to $43.58B.
What does treasury stock mean?: Shares repurchased by the company and held in treasury, reducing equity. Recorded at cost and presented as a negative equity component.